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Abstract. 
Oncolytic viruses offer many advantages for cancer therapy when administered directly to 
confined solid tumors. However, the systemic delivery of these viruses is problematic due to 
host immune response, undesired interactions with blood components and inherent targeting to 
the liver. Efficacy of systemically administered viruses has been improved by masking viral 
surface proteins with polymeric materials resulting in modulation of viral pharmacokinetic 
profile and accumulation in tumors in vivo. Here we describe a new class of polyvalent reactive 
polymer based upon poly(N-(2-hydroxypropyl)methacrylamide) (polyHPMA) with diazonium 
reactive groups and their application in the modification of the chimeric group B oncolytic 
virus enadenotucirev (EnAd). A series of six copolymers with different chain lengths and 
density of reactive groups was synthesised and used to coat EnAd. Polymer coating was found 
to be extremely efficient with concentrations as low as 1 mg/mL resulting in complete (>99%) 
ablation of neutralising antibody binding. Coating efficiency was found to be dependent on 
both chain length and reactive group density. Coated viruses were found to have reduced 
transfection activity both in vitro and in vivo, with greater protection against neutralising 
antibodies resulting in lower transgene production. However, in the presence of neutralising 
antibodies some in vivo transgene expression was maintained for coated virus compared to the 
uncoated control. The decrease in transgene expression was found not to be solely due to lower 
cellular uptake but due to reduced unpackaging of the virus within the cells and reduced 
replication indicating that polymer coating does not cause permanent inactivation of the virus. 
These data suggest that virus activity may be modulated by appropriate design of coating 
polymers while retaining protection against neutralising antibodies. 
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Introduction 
Virus-based therapies for cancer were first proposed over 100 years ago but the first clinical 
trials involving administration of attenuated viruses were of mixed success.(1),(2) As our 
understanding of virology has improved conditionally-replicating viruses that can act as 
anticancer agents (oncolytic viruses)(3),(4),(5) have been developed. These have led to the first 
product, Oncorine, an engineered oncolytic adenovirus approved for the treatment of head and 
neck cancer, being released in China in 2005.(6),(7) More recently, Imlygic, an oncolytic 
herpes virus, has been approved in  US and EU, for the treatment of unresectable melanoma 
lesions.(8) 
The widespread use of oncolytic viruses for disseminated cancers via systemic (i.e. 
intravenous) administration remains limited by virus immunogenicity, and the pharmacokinetic 
and biodistribution profiles of injected nanoparticles.(9-11) Accordingly, there have been 
efforts to target viruses to cancer sites, in a manner analogous to those adopted for targeting 
synthetic nanoparticles.(12-15) The conjugation of synthetic polymerV WR SURYLGH µVWHDOWK¶
coatings for oncolytic viruses is one means by which extended circulation and tumour targeting 
might be achieved. A number of papers have reported successful conjugation of polymers to 
synthetic viruses,(16-18) with concomitant changes in viral biodistribution and targeting.(19-
22) 3(*\ODWLRQRIDGHQRYLUXV$GZDVUHSRUWHGLQWKHSLRQHHULQJZRUNRI2¶5LRUGDQet al.(23) 
and Croyle et al.(24) Adenovirus (Ad) vectors were modified with PEG5000 and were shown to 
retain infectivity and to transduce cells in vitro and in vivo in the presence of neutralizing 
antibodies. Although this was the first example of successfully chemically modified Ad, the 
study was limited to intranasal delivery and a limited degree of PEGylation, due to aggregation 
and precipitation of more highly functionalized viruses. Other polymers have been used to coat 
viruses,(25) of which the most widely used has been poly(N-(2-
hydroxypropyl)methacrylamide) (polyHPMA), covalently bound to the amine groups on the 
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viral surface. polyHPMA with modified side-chains is a polyvalent polymer, thus the coating 
of viral surfaces is more dense with this polymer and lower concentrations are required when 
compared to PEG.(26) polyHPMA for Ad shielding was first developed as a random copolymer 
with pendant amino-reactive 4-nitrophenolate ester linked to polyHPMA by a gly-gly dipeptide 
spacer.(27),(28) In these studies, coating resulted in ablation of Coxsackie-Adenovirus 
Receptor (CAR) binding and conferred partial resistance to neutralizing antibodies. Extended 
plasma circulation was observed for polyHPMA coated virus with higher doses achieving 
longer half-life, to the extent that a 10-fold higher concentration of polyHPMA-Ad was found 
in plasma 30 minutes after injection compared to naked Ad virus. A marked decrease in virus 
hepatotoxicity of Ad upon coating with HPMA polymers, was reported, and additional in vivo 
studies showed accumulation of the conjugate in tumor masses after injection and a 40-fold 
increase in transgene expression compared to unmodified Ad.(29) Coating with this copolymer 
prevented cellular uptake but transfection was restored and boosted when retargeting agents 
such as fibroblast growth factor 2 (FGF2),(30) epidermal growth factor (EGF)(31) or cell-
penetrating peptides(32) were covalently attached. The ability to retarget Ad was evaluated in 
vitro and in vivo where a highly efficient and ligand-dependent transduction was observed. 
However, while a degree of protection against neutralizing antibodies(27),(33) and improved 
pharmacokinetic and biodistribution profiles compared to unmodified-Ad viruses(34) have 
been obtained, complete neutralization of antibody responses by polymer conjugation has still 
to be accomplished. 
Accordingly, we set out to develop new methods for polymer conjugation to viruses in order 
to increase the reaction at the virus surface and therefore enhance the protection against 
neutralising antibodies. Conjugation strategies of polymers to surface viral proteins usually 
LQYROYHVUHDFWLRQZLWKWKHİ-amino groups of lysine residues. The natural abundance of this 
amino acid on viral surfaces, which for adenovirus has been reported to number over 1800 
 Page 5 of 40  
copies(35) make it an important target. However, though the use of this strategy has shown 
relatively high coverage of surface proteins(22-24, 27) as demonstrated by 50 to 80% lower 
anti-adenovirus antibody recognition compared to naked virus, it has failed to produce the 
complete viral antigen masking that is required for the application of viral therapeutics in vivo. 
Herein, we report the synthesis of new polymers with broadened reactivity towards a variety 
of amino acid residues ± potentially overcoming the limitation suffered from specific lysine 
targeting ± and the effects of these polymers on viral vectors in vitro and in vivo. 
Results and Discussion 
Synthesis of functional poly(N-(2-hydroxypropyl)methacrylamide) 
derivatives  
The intial aims were to i) utilise a reactive functional group with broad reactivity and ii) 
determine the effects of polymer chain length and reactive group density on the efficiency of 
polymer coating of an adenoviral vector. EnAd (and reporter transgene derivatives(36)) was 
selected for these studies since intravenous delivery to tumours has been demonstrated with 
this virus,(37) so modifications that improved delivery efficiency or avoidance of neutralizing 
antibodies could have direct therapeutic relevance.  The synthetic approach is outlined in Fig. 
1. PolyHPMA was synthesised via reversible addition-fragmentation chain transfer (RAFT) 
polymerization which allowed polymers of well-defined chain length to be synthesised. In 
previous work, we demonstrated that the pendant secondary hydroxyl group of polyHPMA 
could be modified via a one-step procedure with allyl isocyanate to yield allyl-functional 
reactive polyHPMA derivatives.(38) Here, aniline groups were introduced at different densities 
along the polyHPMA backbone by reaction with Boc-protected aminobenzoic acid followed 
by deprotection of amino groups. The aniline groups could then be activated to form highly 
reactive diazonium groups that would react with the virus surface. The low selectivity of 
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diazonium coupling for specific amino acids at neutral pH was identified as a possible 
advantage that may allow reaction with a wider range of sites on the virus surface leading to 
improved coverage. 
 
 
A series of polyHPMA homopolymers was synthesized as described by Scales et al.(39) The 
chain transfer agent (CTA) to initiator ratios ([CTA]:[I]) were kept constant at 3:1, while the 
HPMA monomer:CTA ratios were varied, (100, 250, 350) to obtain polymers with different 
chain lengths, P1±P3 (Table 1). The end-groups introduced during RAFT polymerization are 
a potential source of toxicity.(40) Consequently they were removed as described by Perrier et 
al.(41) End-group removal was confirmed by UV-Vis spectrophotometry (Figure S1) and 
(OOPDQ¶VDVVD\7able 1), performed before and after treatment. 
Table 1. Poly[N-(2-hydroxypropyl)methacrylamide] precursors 
 
 
 
 
a Calculated considering the initial [HPMA]/[CTA] ratio and final conversion; b 
Determined by SEC using DMF + 0.1 % LiBr as the mobile phase calibrated with PMMA 
standards; c 5HVLGXDOWKLRODIWHU&7$UHPRYDOXVLQJ$,%1DVGHWHUPLQHGE\(OOPDQ¶V
assay.d Below detection limit. 
Pendent aniline groups were attached to the polymer backbone via the coupling reaction of N-
t-butoxycarbonyl-4-aminobenzoic acid with the hydroxyl groups of polyHPMA, using EDC 
Figure 1. Synthetic outline for the production of polymer-coated viruses from polyvalent diazonium salts. 
Reagents: i. N-Boc-4-aminobenzoic acid, EDC, DMAP, DMSO; ii. TBAF; iii. CF3CO2H, NaNO2, sulfamic acid. 
 
Sample 
 
DPn 
Mn, (kDa)   
Theora SECb Ðb %Thiolc 
P1 85 12.2 17.0 1.11 ²d 
P2 165 23.7 30.3 1.14 ²d 
P3 240 34.3 45.9 1.11 0.32 
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and DMAP, as reported by Jones et al. for the esterification of hydroxy-terminated PEG.(42) 
The reactivities of diazonium salts have been demonstrated to increase when electron-
withdrawing groups are introduced in the para position of the aromatic ring, therefore, in 
analogy to data reported by Jones et al.,(42) 4-aminobenzoic acid (PABA) was selected here 
to generate a polymeric diazonium precursor (hereafter referred to as polyvalent diazonium). 
Standard Boc protection of commercially available 4-aminobenzoic acid was carried out to 
afford the pure product (PABA-Boc, Figure S2). The Steglich esterification of alcohols 
mediated by carbodiimides is often carried out in the presence of catalytic amounts of DMAP. 
However, under these conditions, a large excess of DMAP was found to be needed to promote 
the reaction. The optimized reaction was monitored by 1H NMR spectroscopy for 48 h. when 
no further conversion of the alcohol into the corresponding benzoic esters was observed. 
Coupling of PABA-Boc to the PHPMA precursors was tailored to target degrees of 
functionalization of 0.15 and 0.30 aniline groups per initial OH group. Higher modifications 
(0.5) resulted in unusable water-insoluble polymers after deprotection while lower 
modifications (0.10 or single terminal modification) failed to undergo later diazo coupling 
when bioconjugation was tested with a model protein (data not shown).  
Benzoic acid content in the final products was quantified by 1H NMR spectroscopy by 
comparing the reference integral values of the propyl CHO, whose summed value was assigned 
to 1 proton, and the integrals of the aromatic protons or the NH proton of the Boc protecting 
group. To validate the results, alternatively, the signal of the Boc NH was used as a reference 
and compared to values of polyHPMA signals. Polyvalent diazonium precursors were treated 
with 8 equivalents of tetrabutylammonium fluoride (Bu4NF) to aniline groups at 80 °C for 16 
h in DMSO in order to remove the protecting group. The reaction yielded the desired aniline-
modified polymers with only limited hydrolysis of the ester groups. 1H NMR spectroscopy was 
used to assess the removal of Boc groups and to determine the final aniline content (Figure 2). 
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Six polyvalent diazonium precursors were generated using this method with 3 different chain 
lengths and 2 degrees of functionalization (Table 2).  
As these polymers bear multiple activated aromatic rings in close proximity to each other, there 
is significant potential inter- and intra-molecular side reactions that would effectively limit the 
number of diazo groups available for coupling to the desired target. Consequently, the ability 
of polydiazonium polymers to react completely to give the required diazo-adducts was tested 
and monitored by 1H NMR spectroscopy. The shift in aromatic signals of the aromatic groups 
in the 1H NMR spectra were used to monitor conversion at each step of the synthesis (Figure 
3). 
Table 2. Degree of functionalization of PHPMA precursors after post-polymerization 
modification with N-Boc-4-aminobenzoic acid and subsequent deprotection. 
Figure 2. 1H NMR spectrum of deprotected P9 in DMSO-d6. All polymers in the 
P4±P9 library gave analogous spectra, where only the relative intensity of the 
PABA-Boc and HPMA repeating units was found to change. 
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 Composition PABAtarg (%)a PABAcalc (%)b,c PABAdep (%)c,d 
P4 HPMA85-r-PABA9 15 11 10 
P5 HPMA85-r-PABA20 30 24 24 
P6 HPMA165-r-PABA18 15 12 11 
P7 HPMA165-r-PABA40 30 25 25 
P8 HPMA240-r-PABA22 15 12 9 
P9 HPMA240-r-PABA58 30 26 24 
a
 targeted based on the initial HPMA:PABA ratio; b after esterification; c calculated using 
1H NMR spectroscopy in DMSO-d6; d after deprotection with Bu4NF.  
Diazonium salts of P7 were generated by sequential addition of TFA and NaNO2 to an aqueous 
solution of the polymer at 0 °C to form the nitrous acid required to convert the PABA repeating 
units into their corresponding diazonium salts in situ. Excess nitrous acid was quenched and 
with sulfamic acid and the pH adjusted to 7.4 for subsequent protein conjugation. Control of 
the reaction temperature was essential for successful diazonium formation with small increases 
due to addition of mild/warm solutions resulting in decomposition.  
Polyvalent diazonium polymers provide efficient shielding of EnAd 
against neutralizing antibodies in vitro 
Efficient shielding of the viral surface is essential to prevent recognition, and subsequent 
destruction, by the immune system. Consequently, the ability of polyvalent diazonium 
polymers to effectively shield EnAd from neutralizing antibodies was evaluated. The series of 
Figure 3. Stacked aromatic region of 1H NMR spectra of the 
various stages of diazonium salt formation: aniline precursor 
(black, top), protonated aniline (green, middle) and diazonium 
salt (blue, bottom). 
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polymers synthesized allowed three variables in the coating to be assessed: the density of 
diazonium moieties on the polymer chain (i.e. 10 and 24 mol %); the copolymer degree of 
polymerization (i.e. 85, 165 and 240 units) and the concentration of the copolymers in the 
conjugation reaction (0.5 to 5.0 mg/mL). The EnAd concentration was kept constant 
throughout. 
The bioconjugation of polyvalent diazonium polymers to was first tested using BSA as a model 
protein (Figure S3). For virus bionconjugation, stock solutions of P4 to P9 were activated in 
situ and added to the required virus aliquot on ice. Three independent experiments were 
performed with triplicate samples of each formulation. The efficiency of coating was estimated 
using an enzyme-linked immunosorbent assay (ELISA) with antibodies for EnAd. Briefly, 
anti-Ad antibody (polyclonal rabbit) was immobilised on an ELISA plate to act as a capture 
antibody then solutions of unmodified and polymer-coated EnAd were added. The amount of 
captured EnAd was determined by addition of anti-Ad antibody (polyclonal mouse) which was 
detected using an anti-mouse HRP secondary antibody with ¶¶-tetramethylbenzidine 
(TMB) as the substrate. The absorbance relative to unmodified EnAd was then used to estimate 
Figure 4. EnAd shielding from neutralizing antibodies as a 
means of determining polymer coating efficiency determined 
via ELISA. Values are normalized to uncoated virus control. 
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shielding efficiency i.e. a lower absorbance indicates less bound EnAd and therefore more 
efficient coating . Represntative results for the six polymers are shown in Figure 4. 
At a polymer concentration of 5 mg/mL, the formation of a yellow precipitate was observed 
after coating with the polymers carrying the higher diazonium content (~24 mol%) indicating 
the formation of undesired cross-linked viral particle aggregates. Conversely, the lower 
diazonium content polymers (~10 mol%) did not produce sufficient viral shielding, with the 
intermediate chain length (DP = 165) achieving around 60% protection against neutralising 
antibodies. Unexpectedly, the absorbance of EnAd-P8 exceeded the value observed for the 
uncoated viral control which would indicate an increase in antibody binding. This was 
attributed to the combined effect of inefficient polymer coating, resulting in significant 
antibody binding, and the absorbance in the same spectral region as the ELISA substrate (450 
nm)(43) of any azobenzene linkages present.  
As cross-linked aggregates are potentially too large for systemic delivery, polymer 
concentrations of 1, 0.75 and 0.5 mg/mL were investigated to reduce the possibility of polymer-
mediated crosslinking. The optimal coating concentration was found to be 1 mg/mL at which 
all polymers provided viral shielding without the formation of precipitates or aggregates, as 
confirmed by dynamic light scattering (DLS, table 3). Lower polymer concentrations resulted 
in insufficient and highly variable coating efficiency (data not shown). At 1 mg/mL polymer 
concentration, the coating efficiency of polymers with low aniline content (10 mol%) increased 
with polymer Mn, indicating that larger polymers do improve shielding, with viral shielding as 
high as 90%. High coating efficiency ± defined as reaching 99% viral shielding from 
neutralising antibodies ± was obtained with polymers with higher aniline content (24 mol%), 
independent of the degree of polymerization. It is worth noting, that EnAd-P4, EnAd-P6 and 
EnAd-P8 (10 mol % diazonium) showed higher variability in the outcome of the coating within 
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the triplicate experiments, indicating that a higher diazonium content might be required to 
increase the reproducibility of the coating. 
Table 3. Hydrodynamic diameter of polymer-coated virus at 1mg/mL coating concentration. 
 diameter (nm) PDI 
EnAd 99 ± 1.7 0.1 ± 0.0 
EnAd-P4 100 ± 1.6 0.1 ± 0.0 
EnAd-P5 107 ± 1.5 0.1 ± 0.0 
EnAd-P6 110 ± 2.9 0.1 ± 0.0 
EnAd-P7 133 ± 1.0 0.2 ± 0.0 
EnAd-P8 108 ± 7.2 0.1 ± 0.1 
EnAd-P9 153 ± 6.9 0.1 ± 0.0  
 
Dynamic light scattering (DLS) analysis of the polymer-coated virus formulations, indicated 
an increase in the hydrodynamic diameter upon coating that can be related to the polymer chain 
length and capsid shielding (table 3). EnAd-P4, EnAd-P6 and EnAd-P8, which displayed less 
antibody shielding by ELISA, did not present significant increases in their sizes compared to 
unmodified virus. EnAd-P5, EnAd-P7 and EnAd-P9, displayed an increase in the diameter 
that was polymer chain length-dependent, in agreement with the polymer shielding observed 
by ELISA. 
Previous reports of polymer-coating viruses with polyHPMA have relied upon active esters 
(e.g. nitrophenolates) as the reactive moiety with surface amines (lysines) as the target on the 
viral capsid. Typically, active ester chemistries have required high polymer concentrations (20 
mg/mL) to achieve antibody shielding with 50±70% reduction in binding as estimated by 
ELISA.(33),(34),(31) Consequently, achieving high levels of shielding (up to 99%) at low polymer 
concentrations (1 mg/mL) demonstrates the benefit of using diazonium groups as the reactive 
species. 
In vitro and in vivo luciferase expression of polymer-coated EnAd 
Although polymer coating can prevent antibody binding, it can also affect the biological 
activity of the virus by preventing interactions with cell surfaces (and thus viral uptake) and 
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viral unpacking (and thus gene expression and virus replication). To determine whether EnAd 
activity was affected by coating, a luciferase-expressing EnAd (EnAd(luc)) was coated as 
before and luciferase expression determined in HT-29 (epithelial colorectal adenocarinoma) 
cells. EnAd has previously been shown to display high oncolytic potency against this cell line 
with a 2-fold increase compared to Ad5(44) and it was therefore selected as an optimal model 
to assess its biological activity. Prior to these studies, cell metabolic activity was determined 
using an MTS assay 24 h. after exposure to the polymers alone (Figure S4). As no significant 
toxicity was found for these polymers at the concentration used and there was relatively little 
free polymer in a model reaction (Figure S3d), all the experiments were performed with virus-
polymer conjugates without extensive purification from unreacted polymer. 
Cells were treated with polymer-coated EnAd(luc) and an uncoated control and the luciferase 
expression was measured 24 h. post infection (Figure 5a). Transduction efficiency was 
markedly reduced for coated EnAd(luc) with up to 4-orders of magnitude reduction in 
luciferase expression compared to the uncoated control. There is no clear correlation between 
the shielding from neutralizing antibodies and the transduction efficiency, with virus coated 
with P8, which displayed high shielding efficiency at 1 mg/mL coating concentration, having 
one of the highest luciferase levels. Polymers with the higher level of diazonium modification, 
which showed more consistent and efficient coating, all reduced luciferase expression to the 
same level. 
As in vitro results do not necessarily translate in vivo, EnAd(luc)-P4 to P9 were screened on 
naïve Balb/C mice to test gene transduction in vivo in the presence or absence of neutralizing 
serum (Figure 5b±d). Groups of three mice were injected intramuscularly with 1 × 109 
vp/mouse. Luciferase expression was imaged using an IVIS imaging system and quantification 
performed at the site of injection, (Figure 5d, red circle). 
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When polymer-coated viruses were administered using phosphate-buffered saline (PBS) as the 
vehicle (Figure 5b), the luciferase expression was reduced in comparison to the uncoated virus 
in a similar manner to that seen in vitro albeit to a lesser extent. When neutralizing serum was 
used as a vehicle (Figure 5c and d), luciferase expression of the uncoated virus was reduced 
approximately 1000-fold compared to administration in PBS, demonstrating the high 
susceptibility of EnAd to neutralisation. Under these conditions, all formulations except 
EnAd(luc)-P9 showed a reduction in transfection compared to administration in PBS. 
EnAd(luc)-P9 maintained a significant level of luciferase expression, while expression levels 
similar to that of the uncoated control were observed for formulations EnAd(luc)-P5 to 
EnAd(luc)-P7. EnAd(luc)-P4 and EnAd(luc)-P8, which showed poor shielding in the ELISA, 
maintained more expression than the uncoated control but not to a significant level. These 
results indicate that polymeric features play an important role in imparting protection against 
Figure 5. Transduction efficiency in vitro (a) and in vivo (b±d) of EnAd(luc) at 1 mg/mL polymer coating. a) 
Luciferase expression of HT-29 cells infected with 500 vp/cell of EnAd(luc) or polymer-coated EnAd(luc), 
measured 24 hours post infection. b, c and d) In vivo luciferase expression after intramuscular injection in Balb/C 
mice of 1 × 109 virus samples in PBS (b) and in neutralizing murine serum (c, d), measured at 24 hours post-
injection using an IVIS imaging system. (Means of triplicate values and standard deviation, one-way ANOVA 
statistical analysis; graph a: p < 0.0001 vs EnAd(luc), ns vs uninfected cells (nil))(n=3),graph b; p=0.0255, graph 
c: p=0.0392.  
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neutralising antibodies in vivo, with both longer polymer chain length and higher analine 
content being required to ensure sufficient protection. 
Polymer coating delays EnAd cellular uptake and transgene expression 
EnAd(luc)-P9 was selected for further investigations in order to obtain a better understanding 
of the intracellular mechanisms involved in the loss of viral activity after polymer coating. To 
allow separation of the effects of polymer coating on cell uptake and later downstream 
SURFHVVHV VXFK DV YLUXV XQSDFNLQJ DQG WUDIILFNLQJ D ³UHWDUJHWHG´ YLUXV ZDV DOVR SURGXFed. 
Poly(lysine) sequences of 6±10 residues are known to interact with cellular membranes via 
electrostatic interactions of the positively charged pendant amino groups and the negatively 
charged phospholipids and increase cell uptake.(45) Therefore, P9 was functionalized with 
1 mol% of oligolysine consisting of 7 amino acids (K7) (Figure S5) which was then used to 
coat EnAd.  
Uptake of EnAd(luc), EnAd(luc)-P9 and retargeted virus, EnAd(luc)-P9-K7, viruses was 
quantified by qPCR. Cells were washed three times with PBS adjusted to pH 3 in order to 
detach any membrane-associated virus that could contribute to false positive results. The 
different uptake profiles of the three formulations are shown in Figure 6 where the coated virus, 
EnAd(luc)-P9, demonstrated a reduction in uptake compared to both EnAd(luc) and 
EnAd(luc)-P9-K7. 
Re-targeting not only restored uptake compared to EnAd(luc)-P9 but was able to markedly 
improve it, most likely due to an increased interaction with the cell membrane that facilitated 
uptake through endocytic pathways other than receptor-mediated.(45) However, these results 
indicate that, although cellular uptake was involved in loss of transduction observed, this may 
not have been the only factor involved as the level of uptake was still high.  
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Later time points were investigated to determine if the polymer coating was causing a delay in 
the unpackaging, a reduction of viral infectivity or a permanent inhibition due to hampered 
intracellular trafficking. HT-29 cells were infected for 1.5 h., washed with acidic PBS as 
described for the uptake studies, and incubated for 24, 48 and 72 h. Cells were then lysed and 
viral genome copies (qPCR) and transgene expression (luciferase assay) determined (Figure 7a 
and b). EnAd(luc) was able to replicate within the one day post infection, which corresponded 
to a high transgene expression (103 increase). Conversely, no significant replication was 
determined up to 3 days post-infection with EnAd(luc)-P9 and EnAd(luc)-P9-K7. However, 
during the same time-course a steady increase of transgene expression became evident, with a 
faster expression mediated by EnAd(luc)-P9-K7. Luciferase expression is controlled by the 
immediate-early CMV promoter and requires partially disassembled virus escaping the 
endosome and reaching the cytoplasm.(46) These results indicate that the polymer-coating 
induces endosomal acculmation, or a delay in the unpackaging of the viral capsid, rather than 
a permanent inhibition. Accumulation in localised organelles at an early stage of infection was 
further confirmed by confocal fluorescence microscopy imaging (Figure S6).  
Figure 6. Viral uptake 1.5 hours post-infection. Viral genome copies were quantified by 
qPCR after three acid washes (PBS pH 3) to detach any membrane associated virus from 
the cells. Samples were prepared and analyzed in triplicate. Statistical analysis 
performed by one-way ANOVA, **** p < 0.0001. 
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7KH³VSHFLILFWUDQVGXFWLRQHIILFLHQF\´GHILQHGDVWKHUDWLRRIWUDQVJHQHH[SUHVVLRQSHUJHQRPH
copies of internalised virus, seems to corroborate this hypothesis (Figure 7c). For EnAd, this 
increased in time until 72 h, when a drop was observed due to cell death. EnAd(luc)-P9 showed 
a small increase in transduction efficiency in the same time-frame. Up to 48 h., 
EnAd(luc)-P9-K7 transduction efficiency was comparable to that of unmodified EnAd(Luc). 
However, a spike in luciferase activity was observed at 72 hours which may have arisen through 
different mechanisms such as the increased uptake of EnAd-P9-K7 and the possibility of K7 
aiding endosomal escape through membrane disruption by the charged alkyl amines.(47) 
To investigate the effect of polymer-coating on replication, cell monolayers were infected with 
EnAd engineered to express green fluorescent protein (GFP) after replication has started 
(endogenous promoter SA, EnAd(SA)). EnAd(SA) was coated as before. The ability of 
EnAd(SA) to produce GFP positive cells allowed for visual observation of replication by 
fluorescence microscopy. Cells were infected with EnAd(SA), EnAd(SA)-P9 and EnAd(SA)-
P9-K7 and imaged for up to 5 days post infection (Figure 8a). 
For EnAd(SA), GFP expression was detectable at 1 day post infection and achieved the highest 
levels at day 2; limited fluorescence was detected at day 3 due to significant cell death. 
Figure 7. Viral disassembly and replication. Cells were infected with 500 vp/cell for 1.5 hours, washed three times 
with PBS pH 3 and, subsequently incubated at 37 °C, 5% CO2. Cells were lysed with 1x reporter lysis buffer at 
1.5, 24, 48 and 72 h. post-infection. 25 µL of lysate was used to quantify viral genome copies by qPCR (a) and 
/ WRTXDQWLI\ WUDQVJHQH H[SUHVVLRQE\ OXFLIHUDVH UHSRUWHUDVVD\ E&³6SHFLILF WUDQVGXFWLRQHIILFLHQF\´
calculated as RLU/genome copies ratio. 
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EnAd(SA)-P9 and EnAd(SA)-P9-K7 did not induce any significant fluorescence until 5 days 
post infection. Quantification of green fluorescence in the samples was performed by flow 
cytometry (Figure 8b). For EnAd, 60% of cells were GFP positive after two days. As observed 
by fluorescent microscopy, both the polymer-coated formulations, EnAd(SA)-P9 and 
EnAd(SA)-P9-K7, showed a slow onset of fluorescence which markedly increased at 5 days 
post infection at which point 80% of cells treated EnAd(SA)-P9-K7 were GFP positive. This 
enchancement of transgene expression is attributed to enhanced cell uptake provided by the K7 
targeting. 
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Figure 8. Green fluorescence micrographs (a) and percentage of fluorescent cellls (b) for HT-29 cells 
infected with EnAd(SA) GFP. Cells were infected with 100 vp/cell of EnAd(SA)-GFP, EnAd(SA)-
P9, EnAd(SA)-P9-K7. Images were recorded every 24 h. for 5 days using a widefield inverted 
microscope equipped with a green fluorescence filter. After imaging, cells were fixed for 
quantification using flow cytometry. Cells were detached from the well and fixed in 4 % PFA for 10 
minutes at 4 C. After centrifugation, the pellet was resuspended in PBS and the percentage of GFP 
positive cells were quantified by flow cytometry. 
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These data together confirmed that the ability of  EnAd(SA)-P9  to replicate is not permanently 
hampered. The delayed onset of expression is in agreement with the delay in unpackaging, and 
suggestive that only a small number of viruses participated in the infection at this stage.  
Consideration of the biological mechanisms underlying viral activity provide some 
explanations for the transfection and replication data observed. In EnAd(luc) is regulated under 
a cytomegalovirus (CMV) promoter which, when inserted in exogenous genetic materials, is 
constitutively active and allows luciferase to be expressed even when replication does not 
occur. In naïve mice, EnAd(luc) is replication-incompetent and luciferase expression thus 
reflects only the ability of the virus to enter cells and unpackage intracellularly. It is also 
important to recognise that the receptor used by EnAd, and in general by adenoviruses of 
species B, CD46, is not expressed in rodent cells.(48) For this reason, rodents are not ideal in 
vivo models when employed for testing with adenoviruses that enter cells through interactions 
with this receptor. However, in this study, the use of a rodent in vivo model was designed to 
serve as a µEDFNJURXQGDVVD\¶WRGHWHFWDQ\XSWDNHZKLFKPLJKWRFFXUWKURXJKWKHSOHWKRUDRI
endocytic pathways. In particular, adenoviruses have been shown to induce cellular activation 
of macropinocytosis as a means to enter host cells, as reported by Amstutz et al. and Kalin et 
al. (49),(50),(51)  for macropinocytic uptake of Ad3 and Ad35 in epithelial cells, respectively. 
These viruses also use CD46 as a receptor for epithelial cellular uptake, and thus can be 
considered to be analogous to EnAd in their cell internalisation properties. Both transgene 
expression and virus internalization assays in this study supported the hypothesis that different 
mechanisms, other than CD46 clathrin-dependent endocytosis, are involved in the 
internalization of EnAd. In addition, luciferase expression in vivo following polymer-coated 
EnAd administration was partly restored compared to that observed in the in vitro experiments. 
Interestingly, the effect of the different polymers resembled the trend observed for the in vitro 
screening and ELISA previously described. These data suggested that ligand-receptor 
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interactions play a pivotal role in ablating the activity of polymer-coated viruses in vitro but 
are not essential when the latter are administered in vivo. Polymers with higher diazonium 
content (EnAd-P5, EnAd-P7 and EnAd-P9) and EnAd-P6 could only partially restore 
transduction in vivo, with EnAd-P9 recovering higher levels of luciferase expression compared 
to the other formulations. In a similar fashion, polydiazoniums of higher Mn (EnAd-P8 and 
EnAd-P9) imparted enhanced protection against neutralizing mouse serum as compared to 
uncoated EnAd (Figure 5c and d). It is important to notice that although similar capsid-
shielding and in vitro activity profiles were observed for EnAd-P5, EnAd-P7 and EnAd-P9 
formulations, lower luciferase expression was induced by EnAd-P5 and EnAd-P7. Taken 
together, these data allowed an insight into a structure-activity relationship of the investigated 
polymers which suggest that for the same content of reactive side-chain functionality, an 
increase in polymer size is favourable for both shielding and de-targeting purposes. It could be 
hypothesized that polymer coating interferes at the intracellular level, altering or limiting its 
natural trafficking. Successful infection by a virus relies on the delivery of viral genetic 
material to the host cell nuclei. A polymer that is too tightly bound to the viral surface could 
disrupt the tertiary structure of capsid proteins or sterically prevent capsid disassembly or 
endosomal escape, thus reducing the overall progress of the infection. When considering 
EnAd-P5 and EnAd-P9 (chain lengths 85 and 240, respectively) it might be expected that 
EnAd-P9 would produce lower transgene expression in vivo compared to EnAd-P5 due to the 
larger volume of the polymer. The result obtained could be attributed to the fact that a shorter 
polymer chain (polyHPMA P1, Mn ~ 12 kDa) can facilitate diazonium coupling by an increased 
exposure of the active groups compared to a more coiled and sterically hindered conformation 
of a longer polymer chain (pHPMA P3, Mn ~ 35 kDa). This would result in fewer azobenzene 
bonds being formed on EnAd-P9 and a looser polymer coating, which is in agreement with the 
DLS results, through which prevention of antibody recognition would be mediated by steric 
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hindrance of this flexible and coiled structure as well as chemical blocking recognition sites. 
Consequently, EnAd-P9 might allow increased viral disassembly compared to EnAd-P5 or 
EnAd7 as this looser coating will be more flexible. In contrast, if the polymer chains were 
tightly bound to the virus surface, capsid disassembly would be hindered. Since the DLS data 
demonstrated a marked increase in hydrodynamic volume of virus formulations as the polymer 
Mn increased, it is therefore likely that the longer polymers (EnAd-P6 and EnAd-P9) bound 
in a more open structure to the virus surface. In turn, this higher entropy structure enhanced the 
steric shielding against large antibodies but did not completely prevent viral replication 
processes which arose through disassembly of smaller components at the viral capsid. 
Conclusions 
In this study, a novel set of functional polyHPMA-based materials bearing multiple diazonium 
salts was readily generated by simple and well-established coupling techniques via post-
polymerization modifications. The broadened reactivity spectrum of diazonium salts towards 
various amino acids enabled optimized shielding of EnAd adenoviral capsid against 
neutralising antibody at polymer concentrations of 1 mg/mL, 10±20 fold lower than that 
reported in literature, as demonstrated in vitro and in vivo. Polymer chain length were found to 
be a key factor in both virus shielding and modulation of activity. Importantly, irreversible 
polymer conjugation with larger polymers did not result in permanent inactivation, as 
highlighted by time-course transgene expression and viral genome quantification, but likely a 
delayed unpackaging caused by impaired cellular trafficking. These data suggest that by further 
tailoring the polymer macromolecular features, it may be possible to tune key pharmaceutical 
properties of polymer-virus conjugates, such as circulation time, resistance to neutralising 
antibodies, internalisation and intracellular trafficking at target cells and to preserve viral 
activity. 
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Materials and Methods 
Materials 
1-amino-2-propanol (>99%), methacryloyl chloride (97%), (4-cyanopentanoic acid)-4-
dithiobenzoate (CPADB), 4,4'-azobis(4-cyanovaleric acid) (V-501, >90%), 
azobis(isobutyronitrile) (AIBN, 98%), Fmoc-lysine(Boc), EDC (1-ethyl-3-(3-
dimethylaminopropyl) carbodiimide), DMAP (4-dimethylamino pyridine),  trifluoroacetic acid 
(TFA, 99%), sulfamic acid and triethylamine (TEA, >98%), Tris- Ethylenediaminetetraacetic 
acid (Tris-EDTA) were purchased from Sigma-Aldrich (Poole, UK). Sodium nitrite was 
purchased from Fluka. Di-tert-butyl-dicarbonate (97+%) were purchased from Alfa Aesar. 
Piperidine (>99%), anhydrous (<50 ppm water) N,N-dimethylacetamide (DMAc) and 
anhydrous (<50 ppm water) dimethylsulfoxide (DMSO) were purchased from Acros Organics 
(Geel, Belguim). 2-(7-Aza-1H-benzotriazole-1-yl)-1,1,3,3-tetra-methyluronium 
hexafluorophosphate (HATU, 98%) was purchased from Fluorochem Ltd (Hadfield, UK). H- 
1RYD6\Q7*7UHVLQZDVSXUFKDVHGIURP1RYDELRFKHP+LJKJOXFRVH'XOEHFFR¶VPRGLILHG
(DJOH¶V 0HGLXP '0(0 ZLWK /-JOXWDPLQH 'XOEHFFR¶V SKRVSKDWH EXIIHU VDOLQH '3%6
+DQN¶VEDODQFHGVDOWVROXWLRQ+%66IHWDOERYLQHVHUXP)%6ZHre purchased from Fisher 
scientific UK as well as all other chemicals and solvents (analytical or HPLC grade). AIBN 
was recrystallized from MeOH and methacryloyl chloride was distilled under Ar flow before 
use, all other chemicals were used as received unless otherwise stated. EnAd adenoviruses were 
supplied by PsiOxus Therapeutics: EnAd, EnAd(luc) (expressing firefly luciferase under CMV 
promoter), EnAd(SA) GFP (expressing green fluorescent protein under control of splicing 
acceptor).  
Analytical Methods 
Nuclear magnetic resonance (NMR) spectra were recorded on a Bruker Avance III 400 MHz 
spectrometer. All chemical shifts į are reported in ppm relative to tetramethylsilane or 
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referenced to the chemical shifts of residual solvent resonances. Multiplicities are described 
with the following abbreviations: s = singlet, br = broad, d = doublet, t = triplet, m = multiplet. 
Mass spectrometry was carried out using a Micromass LCT ToF with electrospray ionization 
and OpenLynx software. Samples were prepared in 1:1 MeCN/water containing 0.1% v/v 
formic acid. Size exclusion chromatography (SEC) was performed on a Polymer Laboratories 
GPC 50 system equipped with a refractive index detector. Separations were achieved with a 
pair of PLgel Mixed-'ȝPEHDGîPP) columns with a matching guard (7.8 × 50 
mm) and DMF containing 0.1% LiBr as eluent at a flow rate of 1 mL min-1. Calibration was 
performed using narrow PMMA standards (Polymer Labs) in the molecular weight range 1-
1200 kDa. Molecular weights and dispersity values were calculated using Cirrus GPC 3.0. 
Aqueous SEC was performed on Shimadzu Prominence UPLC system fitted with a DGU-20A5 
degasser, LC-20AD low pressure gradient pump, CBM-20A LITE system controller, SIL-20A 
autosampler and an SPD-M20A diode array detector. Separations were performed on a PL 
Aquagel-OH 30 column (7.5 × 300 mm) with a mixture of 3:7 MeOH:PBS at a flow rate of 1.0 
mL min-1 as the mobile phase. 
Synthesis of N-(2-hydroxypropyl)methacrylamide (HPMA) 
HPMA was prepared as previously described.(52, 53) Briefly, 1-amino-2-propanol (30 g, 0.40 
mol) was dissolved in CH2Cl2 (800 mL) followed by the addition of solid NaHCO3 (36 g, 0.44 
mol). Freshly distilled methacryloyl chloride (40 g, 0.38 mol) was dissolved in CH2Cl2 (60 
mL) and added to the suspension dropwise over the course of 1 h, at 0 °C. The reaction was 
allowed to proceed for 3 h. at room temperature. The suspension was filtered and the solvent 
removed under reduced pressure. The crude residue was recrystallized from acetone twice and 
the crystals dried under vacuum (42 g, 0.29 mol, 73%). 1H NMR (400 MHz, CDCl3į 
(br, 1H, NH), 5.73±5.69 (m, 1H, vinyl Z to Me-C=C), 5.37±5.30 (m, 1H, vinyl E to Me-C=C), 
4.00±3.85 (m, 1H, CHOH), 3.53±3.43 (m, 1H, CHaN), 3.28±2.95 (m, 2H, CHbN + OH), 1.95 
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(s, 3H, C=C-CH3), 1.18 (dd, J = 6.3, 1.9 Hz, 3H, CH3). 13&1050+]&'&Oį 
169.55 (1C, C=O), 139.62 (1C, C=CH2), 120.13 (1C, C=CH2), 67.03 (1C, CHOH), 47.19 (1C, 
CH2), 20.89 (1C, CHCH3), 18.66 (1C, CCH3). FT-,5ȞFP-1) = 3337, 2973, 1655, 1614, 1541. 
ESI-TOF-MS: m/z found 144.1011, [M+H]+ requires 144.0980. 
Synthesis of polyHPMA homopolymers 
PolyHPMA homopolymers were synthesised by RAFT polymerization of HPMA following a 
known standard protocol.(39) %ULHÀ\IRU the synthesis of pHPMA P1: HPMA (4.0 g, 28 mmol) 
was dissolved in acetate buīer (40 mL, pH 5.2, 1.0 M) along with CPADB (79 mg, 0.28 mmol) 
and V-501 (26 mg, 0.092 mmol). The solution was bubbled with nitrogen for 40 min before 
heating to 70 °C. Aliquots were taken periodically to monitor monomer conversion by 1H NMR 
spectroscopy. Once a conversion of 70ʹ85% was reached, the polymerisation was stopped by 
FRROLQJWKHVROXWLRQLQDQLFHEDWKDQGH[SRVLQJLWWRDLU3RO\PHUVZHUHVXEVHTXHQWO\SXUL¿HG
E\GLDO\VLVDJDLQVWZDWHUDFLGLILHGZLWK+&OS+íXVLQJDN'D0:&2PHPEUDQHIRU
24 h and isolated by lyophilization. 1H NMR (400 MHz, DMSO-Gį EURDGV+
CONH), 4.75 (broad s, 1H, CHOH), 3.76 (broad s, 1H, CHOH), 3.02 (broad s, 2H, CH2), 
íEURDGP+&+2 and CH3 of backbone and CHCH3). 
Chain Transfer Agent (CTA) end-group removal 
Removal of the end group was performed according to the procedure described by Perrier et 
al.(41) A 30-fold molar excess of AIBN with respect to the chain transfer agent was employed. 
polyHPMA and AIBN were dissolved in dry DMSO and the solutions were bubbled with 
nitrogen for 35 min then heated to 80 °C for 3 h under continuous stirring. The resulting 
solutions were dialyzed against water for 24 h and subsequently lyophilized. The final thiol 
concenWUDWLRQ ZDV FDOFXODWHG XVLQJ D VWDQGDUG (OOPDQ¶V DVVD\(54) 1H NMR (400 MHz, 
DMSO-d6į EURDGV+&21+EURDGV+&+2H), 3.76 (broad s, 1H, 
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CHOH), 3.02 (broad s, 2H, CH2íEURDGP+&+2 and CH3 of backbone and 
CHCH3). 
Synthesis of N-t-butoxycarbonyl-4-aminobenzoic acid 
N-t-butoxycarbonyl-4-aminobenzoic acid was synthesized according to the protocol reported 
by Jones et al.(42) In a round bottomed flask, 4-aminobenzoic acid (2.5 g, 18 mmol) was 
dissolved in a mixture of 1,4-dioxane (35 mL) and water (20 mL). Triethylamine (5.0 mL, 37 
mmol) was added to the solution and left under stirring for 10 minutes before addition of solid 
di-tert-butyl dicarbonate (8.0 g, 37 mmol). The reaction was allowed to proceed for 24 h. at 
room temperature. The solvent was removed under vacuum, then HClaq (3 M, 35 mL) was 
added to the residue to obtain a white precipitate that was recovered by filtration and freeze 
dried. The product was crystallized from hot methanol to yield N-t-butoxycarbonyl-4-
aminobenzoic acid as a white solid (3.9 g, 91%). M.p. found 197-199 °C, reported 192-194 
°C.(55) .1H NMR (400 MHz, DMSO-Gį V+&21+G+- +]
CHarom), 7.55 (d, 2H, J = 8.9 Hz, CHarom), 1.47 (s, 9H, 3 CCH3). 13C NMR (100 MHz, DMSO-
d6įSSP&&22+&&21+&CCOOH), 130.4 (2C, CH), 
124.0 (1C, CHNH), 117.2 (2C, CH), 79.7 (1C, C(CH3)3, 28.1 (3C, 3 CH3). ESI-TOF-MS: m/z 
found 237.1529, [M+H]+ requires 237.1001. 
General procedure for the synthesis of Poly[HPMA]-r-[N-(2-
hydroxypropyl)methacrylamide±4-(tert-butoxycarbonylamino)benzoate 
poly(HPMA-r-Boc-PABA) 
Synthesis of HPMA-r-Boc-PABA P9: N-t-butoxycarbonyl-4-aminobenzoic acid (268 mg, 1.13 
mmol) was dissolved in dry DMSO (5 mL). DMAP (276 mg, 2.22 mmol) and EDC (433 mg, 
2.22 mmol) were subsequently added and allowed to dissolve under stirring for 10 min, after 
which polyHPMA (540 mg, 3.77 mmol) was added. The reaction was left to proceed for 36 h. 
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at room temperature; conversion was monitored by 1H NMR spectroscopy. The crude product 
was first precipitated from Et2O twice and, subsequently, purified by dialysis against water, 
using a 3.5 kDa cut-off, for 2 days and freeze dried.   1H NMR (400 MHz, DMSO-Gį 
(br s, CONHBoc), 7.87 (br s, CHarom), 7.59 (br s, CHarom), 7.13 (br s, CONHHPMA), 4.96 (br s, 
1H, CHOC(O)), 4.71 (br s, 1H, CHOH), 3.68 (br s, 1H, CHOH), 2.91 (br s, 2H, CH2CH), 2.02- 
0.26 (br m, 17 H, CH2CCH3 backbone, CHCH3 and 3 CH3 Boc). 
General procedure for the synthesis of poly[HPMA]-r-[N-(2-
hydroxypropyl) methacrylamide±4-amino benzoate] poly(HPMA-r-PABA) 
Poly(HPMA-r-Boc-PABA) P9 (450 mg, 0.31 mmol of aniline) was dissolved in dry DMSO (7 
mL) and to the resulting solution tetrabutylammonium fluoride (1.6 mL of 1M solution in THF, 
1.6 mmol) was added. The reaction was allowed to proceed overnight at 80 °C under reflux. 
After cooling to room temperature, the final product was precipitated twice from Et2O and, 
subsequently, purified by dialysis (3.5 kDa MWCO) against water for 1 day, and freeze-dried. 
1H NMR (400 MHz, DMSO-Gį EUV&+arom), 7.16 (br s, CONHHPMA), 6.58 (br s, 
2CHarom), 5.92 (br s, 2H, NH2aniline) 4.94 (br s, 1H, CHOCO), 4.73 (br s, 1H, CHOH), 3.68 (br 
s, 1H, CHOH), 2.91 (br s, 2H, CH2CH), 2.15- 0.25 (br m, 17 H, CH2CCH3 backbone, CHCH3 and 
3 CH3Boc). 
Synthesis of oligolysine-N-Boc (K7) 
A standard solid phase peptide synthesis procedure was used to synthesize oligolysine-N-Boc 
(K7) peptide.(56) Seven N-Fmoc-Lys(Boc) were coupled in sequence to Fmoc-Lys(Boc) 
NovaSyn®TGT resin (750 mg, 0.13 mmol) using HATU as the coupling agent. The N-terminus 
was acetylated using 20% acetic anhydride in dry DMAc for 45 minutes. The peptide was 
cleaved from the resin using 0.1% TFA, 0.5% TIPS in dry DCM, the product dried under 
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reduced pressure and analyzed by HPLC and ESI-MS-ToF. ESI-TOF-MS: m/z found 
1679.3453, 851.5477. [M+Na]+ requires 1680.0421, [M+2Na]2+ requires 851.5477.  
Synthesis of re-targeting of polymer P9 with K7 (P9-K7) 
Polymer P9 (10 mg, 69.8 µmol of monomer units) was dissolved in DMSO-d6 (0.7 mL) along 
with K7 (2.3 mg, 1.4 µmol), EDC (27 mg, 0.140 mmol) and DMAP (4.3 mg, 34.9 µmol). The 
solution was allowed to react under stirring for 24 hours at room temperature. The product was 
purified by precipitation in mixture Et2O: DCM 80:20 and twice in water before freeze drying 
the product. 1H NMR (400 MHz, DMSO-Gį -7.82 (s, 7NHBoc) 7.66 (br s, 2CHarom), 
7.16 (br s, CONHHPMA), 6.58 (br s,2CHarom), 5.92 (br s, 2H, NH2aniline) 4.94 (br s, 1H, CHOCO), 
4.73 (br s, 1H, CHOH), 3.68 (br s, 1H, CHOH), 2.91 (br s, 2H, CH2CH), 2.15- 0.25 (br m, 17 
H, CH2CCH3 backbone, CHCH3 and 3 CH3Boc).  
General procedure for polymer coating of EnAd 
Coating experiments were performed using a 10 mg/mL polymer stock solution. Typically, P9 
(3.0 mg, 5.0 µmol of aniline) was dissolved or suspended in HPLC grade water (150 µL) and 
10% TFA in water (7.7 µL, 10.0 µmol) under stirring. The mixture was allowed to react for 45 
min at room temperature, then cooled with an ice bath. 200 mg/mL NaNO2 and of 150 mg/mL 
sulfamic acid stock solutions in water were placed in ice. Under vigorous stirring, ice cold 
NaNO2 stock solution (3.5 µL) was added and incubated at 0 °C for 1 hour. Ice cold sulfamic 
acid stock solution (6.5 µL) was then added, and after 1 hour at 0 °C, the pH of the solution 
was adjusted to 7.4 with ice cold 500 mM HEPES pH 7.6 (132 µL). Polymer-coated virus stock 
solutions were prepared with a typical final titre of 5 × 1011 vp/mL in 50 mM HEPES buffer 
pH 7.4 at final polymer concentrations of 1 or 5 mg/mL. After addition of the polymer solution 
to the virus suspension, the conjugation reaction was allowed to proceed overnight at 4 °C. 
Formulations were aliquoted, flash frozen in liquid nitrogen and stored at -80°C. 
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Dynamic Light Scattering (DLS)  
Particles size analyses were carried out at 25 °C using a Zetasizer Nano spectrometer (Malvern 
Instruments Ltd) equipped with a 633 nm laser at a fixed angle of 173°. Samples were 
suspended in HEPES buffer pH 7.4 10 mM. 
Enzyme-Linked Immunosorbent Assay (ELISA) 
$0D[L6RUS181&(/,6$SODWHZDVSUHSDUHGE\FRDWLQJZLWK/RIGLOXWLRQRI
polyclonal rabbit anti-Ad capturing antibody (prepared by Morendum Scientific, Penicuik, 
UK) in 0.05 M pH 9.6 carbonate/ bicarbonate buffer overnight at 4°C. After incubation, the 
plate was washed four times with PBS, as for each incubation step of the procedure. Non-
specific binding was prevented by incubation of 200 µL blocking solution, consisting of 5% 
BSA in PBS, for 1 hour. Next, 50 µL of 1 × 109 virus particles (vp)/mL virus formulations in 
blocking solution were incubated for 2 hours at room temperature. 50 µL of a 1:500 dilution of 
polyclonal mouse anti-Ad antibody (prepared in house by PsiOxus Therapeutics, Oxford, UK) 
was added to the wells. After 1 hour incubation at room temperature, 50 µL of 1: 300 dilution 
of goat anti-mouse HRP antibody (secondary antibody) in blocking solution were incubated 
for 1 hour. TMB-ELISA substrate was added to the plate ad incubated 20-30 min before 
stopping the reaction with 1N HCl. Absorbance was read at 450 nm.  
Cell culturing conditions  
For the in vitro studies, HT-29 human colorectal adenocarcinoma cells well cultured according 
to the procedures to the following procedures. Manufacturers or suppliers of reagents and 
equipments are stated where they are first mentioned. Laboratory plastic-ware was received by 
Fisher Scientific or CoUQLQJ ,QF&HOOFXOWXUHPHGLDZDVKLJKJOXFRVH'XOEHFFR¶VPRGLILHG
(DJOH¶V 0HGLXP '0(0 ZLWK /-JOXWDPLQH DQG VXSSOHPHQWHG ZLWK  )%6 ³JURZWK
PHGLD´RU)%6³DVVD\PHGLD´ 
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Cell passage 
HT-29 human epithelial colorectal adenocarcinoma cells were selected for this study (cell 
passage number 16 to 19). Cells were maintained at 37 °C, 5% CO2 in a humidity-controlled 
incubator and all manipulations performed in a class II laminar flow cabinet. Cells were 
passaged when 80-90% confluency was reached. Specifically, cells were washed with PBS 
before treatment with Trypsin-EDTA (5 and 2 mL for T175 and T75 plasma treated flasks 
respectively) for 5-10 min at 37 °C, 5% CO2. After detachment, cells were resuspended in fresh 
10% FBS DMEM containing and split into a new flask containing fresh prewarmed growth 
media (dilution 1:10). 
 
Cell plating 
Cell suspensions were prepared as described above. After trypsinization, cells were pelleted 
and resuspended in DMEM containing 2% FBS (assay media). The concentration of live cells 
was determined using a hemocytometer to count cells and the concentration adjusted to the 
required one with fresh DMEM containing 2% FBS. Finally, cells were seeded into 96 well 
plate using a multi-channel pipette and allowed to attach overnight. 
Luciferase Assay 
Luciferase expression in HT-29 after transduction was measured using a Luciferase Reporter 
Assay System from Promega. Cells were seeded at a density of 30k cells/well on microplates 
in assay media. Infection was carried out with 500 vp/cell of EnAd(luc) formulations for 2 
hours at 37 °C, 5% CO2, followed by three PBS washes and incubation in fresh assay media. 
At the required time point, cells were washed with PBS before addition of 60 µL of lysis buffer. 
The plates were then frozen at -80°C overnight. After thawing the plates to room temperature 
cell lysates were resuspended and 25 µL transferred into half-area black well plates where 25 
µL of luciferin was added. Luminescence readings were recorded for 10 s. as relative 
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luminescence units (RLU). The remaining cell lysates were used for genomic DNA extraction 
and quantification. 
Quantitative PCR (qPCR) 
As described above, cells seeded at 30k cells/well in assay media were infected with 500 vp/cell 
for 2 hours at 37 °C, 5% CO2 in microplates. After this time, cells were washed three times 
with PBS or pH 3 PBS and incubated for up to 72 h. in fresh assay media. At the desired time 
point, media was removed from the wells, 60 µL of 1× reporter lysis buffer were added and the 
plate frozen at -80°C overnight. A standard curve was obtained by addition of a known amount 
of virus to cells directly before addition of lysis buffer and the freezing process. Genomic DNA 
extraction was carried out using a GenElute Mammalian genomic DNA extraction kit as per 
WKHPDQXIDFWXUHU¶VLQVWUXFWLRQV%ULHIO\VDPSOHVZHUHO\VHGZLWKDO\VLVEXIIHUDQGSURWHLQDVH
K at 70°C for 10 min before being loaded onto a DNA binding column. DNA was bound to the 
column and purified using ethanol containing buffers and finally eluted in a Tris-EDTA 
solution. A TaqMan® detection system was used to amplify and quantify genomic DNA from 
the samples. Probes labelled with 6-FDUER[\IOXRUHVFHLQ)$0DW¶DQGWHWUDPHWK\OUKRGDPLQH
7$05$DW¶HQGVIRUZDUGDQGUHYHUVHSULPHUVVSHFLILFIRUEnAd were added to qPCRBIO 
Probe Mix HI-ROX (PCR biosystem) and nuclease-free water added to a final volume of 12.5 
µl per well, to obtain 125 nM of probe and 800 nM primers as final concentrations. 5 µl of 
samples were plated in PCR plates and sealed for DQDO\VLVLQD6WHS2QH3OXV5HDO-Time PCR 
system (Applied Biosystem). The analysis was started at 50 °C for 2 min and 95°C for 10 min 
followed by 40 amplification cycles of 15 s. at 95°C and 90 s. at 60 °C, denaturation and 
annealing/extension steps respectively. Data were analysed using standard settings of 
6WHS2QH6RIWZDUH 
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Metabolic Activity Assay (MTS) 
HT-29 cells were seeded into 96-well plate at a density of 25000 cell/well in 100 µL of assay 
media. Cells were treated with 1 mg/mL dilutions of polymer-coated EnAd in assay media and 
incubated for 2 hours at 37°C, 5% CO2 before replacing the media with fresh one. After 24 
hours incubation, cells were washed with PBS and 120 µL of a solution of MTS in phenol-red 
free assay media (1:6 dilution) added to the well.  The plate was incubated for 30 min at 37°C, 
5% CO2   and the absorbance measured at 400 nm using Wallac 1420 Victor multi-label counter 
RU%LR7HN6\QHUJ\+7PXOWLPRGDOPLFURSODWHUHDGHU  
Live Confocal Microscopy 
Uncoated EnAd was fluorescently labelled with a 20-fold molar excess per viral amine 
(approximately 1800 lysines per particle) of BODIPY-FL (Invitrogen) for 2 hours in 50 mM 
HEPES buffer at pH 7.4. Samples of polymer-coated EnAd were prepared according to the 
procedure described in previously, utilizing a 1 mg/mL final polymer concentration. Coating 
efficiency was tested by ELISA before conducting the experiments. 1 × 105 HT-29 cells were 
seeded on BD poly-L-Lysine glass bottomed 35 mm dishes and cultivated overnight in assay 
media. Cells were then washed with ice cold PBS, incubated in ice cold media (1.5 mL) before 
infection with 1 × 104 virus particles (uncoated EnAd or EnAd-P9- FL) for 1 hour over ice. 
After this time, cells were washed three times with ice cold PBS before addition of 1.5 mL of 
ice cold HBSS 20 mM HEPES buffer. The samples were stored on ice until they were placed 
in the incubation chamber for confocal imaging. Live cell imaging was performed on a LSM 
710 (Carl Zeiss) confocal microscope using a 63× oil immersion objective and a CO2-
controlled incubator at 37 °C.  Image analysis was performed using Zen Lite and ImageJ 
softwares. Images were digitized under constant exposure time, gain and offset. 
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Wide-field fluorescence microscopy 
Samples of polymer-coated EnAd(SA) GFP were prepared according to the procedure 
described previously, utilizing a 1 mg/mL final polymer concentration. Coating efficiency was 
tested by ELISA before conducting the experiments. HT-29 cells were cultured in assay media 
at a density of 5 × 107 cells/well on 24 well plates overnight. Cells were infected with 100 
vp/cell of polymer-coated EnAd(SA)  for 2 hours, before washing three times with PBS. 
DMEM supplemented with 2% FBS was then added and cells incubated at 37 °C, 5% CO2. 
Brightfield and fluorescence images were taken at defined time points using an inverted 
fluorescence microscope (Axiovert 25, Carl Zeiss) equipped with a 10× objective. Images were 
digitized under constant exposure time, gain and offset. After imaging the samples were 
collected for flow cytometry analysis. 
Flow cytometry 
After imaging, the samples were treated with cell dissociation buffer in PBS (Life Sciences) 
until complete cell detachment was obtained. Cells were then transferred into FACS tubes and 
pelleted by centrifugation at 300 g for 5 minutes. The pellet was then fixed using 4% 
paraformaldehyde for 15 minutes at 4 °C, re-pelleted and resuspended in PBS. Fluorescent 
cells were counted using FACSCaliber (Becton Dickinson) and analyzed using CellQuestPro 
and FlowJo software. The experiment was run in triplicate. 
In vivo studies 
All in vivo studies were conducted in accordance with institutional ethics procedures and UK 
Home Office authorisation (Animal Scientific Procedures Act 1986) under project license 
30/2819. Female Balb/C mice were obtained from Charles River Laboratories at 4-6 weeks 
old. Mice were housed in a temperature- and humidity-controlled conditions (20-22 °C) in 
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individually ventilated cages at the John Radcliffe Hospital, Oxford. Mice were given free 
access to sterilised tap water and formulated diets, and exposed to 12 h. light-dark cycles.  
In vivo luciferase expression in the absence and presence of neutralizing 
mice serum 
Samples of the polymer-coated EnAd were prepared according to the procedure described 
above, utilizing a 1 mg/mL final polymer concentration. EnAd stock suspension was diluted in 
PBS or in anti-EnAd hyperimmune mice serum (prepared in-house by PsiOxus Therapeutics) 
to a concentration of 5 × 109 vp/mL.  One intramuscular injection of 1 x 109 virus particles (20 
µL) of each sample was performed in each flank of female naÏve Balb/C mice. Luciferase 
expression was measured at 24 hours post-injection using an IVIS imaging system.  
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